May 27, 2020
Information On Synstock And Impact
BusinessadminSynthetic Biologics, Inc. is a clinical phase company. The company develops therapies to protect intestinal microbiomas while targeting specific pathogenic diseases. The main candidates for Phase II companies are SYN-010, which aims to reduce the effect of methane-producing methane on intestinal microbiomas to treat the cause of irritable bowel syndrome (IBS-C) and SYN-004. which is designed to protect intestinal microbiomas (gastrointestinal (GI) microflora) from the effects of some intravenous antibiotics (IV) commonly used to prevent C. difficile infections (CDI) and […]
